DWM
TEVA icon

Doyle Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Doyle Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,419
Closed -$13K – 705
2019
Q2 		$13K Buy
+1,419
New +$17.1K ﹤0.01% 584
2019
Q1 		– Sell
-1,319
Closed -$20K – 692
2018
Q4 		$20K Buy
+1,319
New +$27K ﹤0.01% 514
2017
Q4 		– Sell
-18,939
Closed -$333K – 172
2017
Q3 		$333K Sell
18,939
-442
-2% -$9.95K 0.06% 112
2017
Q2 		$644K Buy
19,381
+907
+5% +$28.1K 0.12% 73
2017
Q1 		$593K Buy
+18,474
New +$630K 0.12% 76

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return

Doyle Wealth Management's TEVA Position: Q3 2019 in Review

Doyle Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2019, closing a stake of 1,419 shares — an estimated $13K sold.

Doyle Wealth Management first reported a position in TEVA in Q1 2017 and held it in 5 quarters. The position peaked at $644K in Q2 2017. 427 funds tracked by Wall St. Rank hold TEVA as of Q3 2019.

  • Doyle Wealth Management reported no remaining Teva Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Doyle Wealth Management sold 1,419 Teva Pharmaceuticals shares in Q3 2019, an estimated $13K.
  • Doyle Wealth Management first reported a position in Teva Pharmaceuticals in Q1 2017 and held it in 5 quarters.
  • Doyle Wealth Management's Teva Pharmaceuticals position peaked at $644K in Q2 2017.
  • 427 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2019.

Based on Doyle Wealth Management's 13F filing for Q3 2019, filed 5 Nov 2019.